These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15941186)

  • 1. How can pharmacoeconomics be more useful?
    Kozma CM
    Manag Care Interface; 2005 May; 18(5):25-6. PubMed ID: 15941186
    [No Abstract]   [Full Text] [Related]  

  • 2. Health economics--what the nephrologist should know.
    Palmer AJ
    Nephrol Dial Transplant; 2005 Jun; 20(6):1038-41. PubMed ID: 15840678
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoeconomics is coming of age.
    Pizzi L; Singh V
    Clin Pharmacol Ther; 2008 Aug; 84(2):188-90. PubMed ID: 18679179
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality-adjusted life-years as decisionmaker tools to address limitations inherent in number-needed-to-treat/harm values.
    Raisch DW; Nawarskas JJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):99-102. PubMed ID: 19402794
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacoeconomics. Potent drugs, diseases are costly].
    Flaten O
    Tidsskr Nor Laegeforen; 1994 Apr; 114(11):1345-6. PubMed ID: 8079219
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacoeconomics: historical perspective.
    Bootman JL; McGhan WF; Townsend RJ
    Ann Pharmacother; 2006 Mar; 40(3):518-9. PubMed ID: 16478813
    [No Abstract]   [Full Text] [Related]  

  • 7. Double counting and the reporting of cost per event avoided.
    Mullins CD
    Clin Ther; 2006 Apr; 28(4):602-3. PubMed ID: 16750471
    [No Abstract]   [Full Text] [Related]  

  • 8. The power of pharmacoeconomics.
    Healthc Exec; 2000; 15(1):44-5. PubMed ID: 11067028
    [No Abstract]   [Full Text] [Related]  

  • 9. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does willingness to pay per quality-adjusted life year bring us closer to a useful decision rule for cost-effectiveness analysis?
    Polsky D
    Med Decis Making; 2005; 25(6):605-6. PubMed ID: 16282209
    [No Abstract]   [Full Text] [Related]  

  • 11. Considerations in the pharmacoeconomics of glaucoma.
    Hirsch JD
    Manag Care; 2002 Nov; 11(11 Suppl):32-7. PubMed ID: 15357537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics in the era of individualized medicine.
    Waldman SA; Terzic A
    Clin Pharmacol Ther; 2008 Aug; 84(2):179-82. PubMed ID: 18679176
    [No Abstract]   [Full Text] [Related]  

  • 14. [What is a cost-benefit analysis?].
    Müller-Bohn T
    Med Monatsschr Pharm; 2004 Oct; 27(10):328-30. PubMed ID: 15527174
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 16. Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives.
    Trippoli S
    Eur J Intern Med; 2017 Sep; 43():e36. PubMed ID: 28552463
    [No Abstract]   [Full Text] [Related]  

  • 17. What affects the quality of economic analysis for life-saving investments?
    Hahn RW; Kosec K; Neumann PJ; Wallsten S
    Risk Anal; 2006 Jun; 26(3):641-55. PubMed ID: 16834624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinician's perspective on pharmacoeconomics and rheumatology.
    Thielscher C
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S91-5. PubMed ID: 23078957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.